Navigation Links
Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
Date:10/26/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will give two presentations during the “Manufacturing and Bioprocessing Track” at the forthcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 at the Henry B. Gonzalez Convention Center, San Antonio, Texas, on Nov. 3-6, 2019.

On Wednesday, Nov. 6 at 10:30 a.m., Lisa Caralli, Director, Science and Technology, will present “Case Studies in Characterizations and Formulation for your Oral Small Molecule Drugs.” Ms. Caralli will advise on methods to analyze physicochemical and biopharmaceutical data to make early drug development decisions. She will explain how to diagnose and address pharmacokinetic issues, and how the application of the developability classification system can guide the design of drug formulations.

Later on Wednesday, at 11:30 a.m., Catalent’s Lun Xin, Process Development Scientist, will present “Mass Spectrometry Tools for Host Cell Protein (HCP) Analysis.” Attendees will learn about the power of mass spectrometry when applied to HCP analysis and characterization, and Mr. Xin will compare mass spectrometry analysis to traditional, enzyme-linked immunosorbent assay (ELISA) and explore its advantages with regards to identifying and quantifying individual species.

Following the presentations, Catalent will host a networking lunch reception at 12:30 p.m.

During the conference, Catalent scientists will also present 10 scientific posters in Exhibit Hall 234. The posters will cover a range of topics including the prediction of solid dispersion technology, a novel method for high-throughput preformulation screening, and methods for relative quantification of N-glycans from a therapeutic monoclonal antibody.

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify the appropriate development pathway for their early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals, and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California at Davis, Davis, California.

Mr. Xin is a scientist within the Analytical and Formulation Development Group at Catalent’s facility in Bloomington, Indiana. He has extensive experience in developing biological, biochemical and physiochemical assays for biologics characterization, and is a specialist in high-throughput formulation development. Mr. Xin received a master’s degree in biotechnology from Northwestern University, Evanston, Illinois and is currently working towards his doctorate degree in pharmaceutical chemistry at the University of Kansas, Lawrence, Kansas.

For more information, please visit https://www.catalent.com/index.php/news-events/events/AAPS-Pharmsci360.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard@nepr.agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists, at more than 30 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_present_case_studies_on_formulation_design_for_early_phase_molecules_and_discuss_benefits_of_mass_spectrometry_for_hcp_analysis_at_aaps_pharmsci_360/prweb16670447.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent Receives P&G External Business Partner of the Year Award
2. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
3. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
4. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
5. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award
6. Underrepresented minority students receive fellowships in digestive disease and nutrition research
7. UCLA life scientists present new insights on climate change and species interactions
8. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress
9. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
10. Yin-yang effect of sodium and chloride presents salt conundrum
11. Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval ... CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned a ... The company’s solutions are the first Wharton’s jelly allograft product to be recognized as ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski ... with a near term focus on Type 2 diabetes and associated comorbidities. , ... multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead ...
(Date:7/18/2020)... ... 17, 2020 , ... Commercial launch readiness is a critical stage in a ... cure or vaccine, the global economic downturn will only increase price pressures overall for ... and capturing full value from every product launch is critical. However, history shows that ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... have entered into a strategic partnership whereby Catalent will provide support for the ...
(Date:7/22/2020)... (PRWEB) , ... July 22, 2020 , ... Join experts ... John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... the regulating body in China for drugs and medical devices. Specifically, for medical devices, ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
Breaking Biology Technology: